# 1. Financial Performance ## A. Key Figures * **Revenue Growth (like-to-like):** **28%** (ex-1/n impact) · **Retail Health growth:** **32%** * **IFRS PAT:** **₹70 Cr** (Q1) (+94% YoY) * Solvency Ratio: 2.86x (> regulatory minimum of 1.50x) * AUM: more than ₹8,100 Cr (Q1) · Investment Yield (annualized): 7.3% ## B. Revenue Growth * **Robust Core Momentum:** Like-to-like revenue growth of 28% reflects strong underlying demand, with retail health segment outperforming at **32%** growth. ## C. Profitability Trends * **Earnings Acceleration:** IFRS profit after tax nearly doubled year-on-year, driven by operating leverage and disciplined cost management. * **Margin Resilience:** Combined ratio improved 70 bps despite a higher loss ratio, as a **6% reduction in expense ratio** delivered meaningful offset. ## D. Balance Sheet Strength * **Capital Cushion Well Above Minimum:** Solvency ratio remains exceptionally strong at 86x, providing ample buffer against volatility and regulatory requirements. * **Accounting Noise Persists:** Indian GAAP results continue to reflect distortions from the 1/n change, expected to linger for **2 to 3 years**; IFRS remains the preferred reporting standard. ## E. Cash Flow Metrics * **Stable Asset Base:** AUM held flat QoQ despite market movements, supported by a **sizable reinsurance settlement** that neutralized outflows. * **Commission Deferral Impact:** Net commission line pressured by rising deferred commissions, which increased to **~₹50 Cr** from ₹27 Cr, tied to long-term policy deferments under 1/n. --- # 2. Premium & Policy Mix ## A. Key Figures * **Retail vs Group Mix:** **67%** retail · **31%** group · **2%** travel/PA * **Retail Health Premium Growth:** **28%–32%** YoY (volume-driven) * **GWP Growth:** **28%** in Q1 FY'26 · **Net Earned Premium (NEP):** **+20%** under I-GAAP * **Multiyear Policy Contribution to GWP:** Declined from **late 20s%** to **early 20s%** ## B. Retail vs Group Mix * **Stable Core Mix:** Retail-dominant premium composition maintained, with **renewals comprising 60%** of retail health book. * **Volume-Led Retail Growth:** Robust double-digit retail health growth driven almost entirely by **volume expansion**, with negligible ticket size change. * **Strategic Group Shifts:** Recent increase in group loss ratio due to **corporate segment tilt**, not underwriting deterioration; two large MNC wins added profitably with **combined ratio ≤100%**. ## C. Multiyear Policy Impact * **Policy Mix Over Accounting Noise:** Decline in average ticket size attributed to **shift in multiyear policy mix**, not pricing pressure; like-to-like metrics remain stable. * **Strategic De-emphasis of Multiyear Policies:** Intentional reduction in multiyear policy share to early 20s% of GWP, aligning with earnings visibility goals. ## D. GWP vs NEP Shift * **Earnings Timing Drag:** GWP outpaced NEP due to **I-GAAP accounting for multiyear policies** and **UPR treatment of two large MNC contracts**, with **50% of premium deferred to Q4**. * **No Structural Impact:** Temporary loss ratio distortion from upfront expense recognition; **no 1/n adjustments apply** as MNC policies are one-year corporate contracts. --- # 3. Claims & Underwriting ## A. Key Figures * Combined Ratio (IFRS): 103.2% Q1 FY26 (improved from 103.9%) * **Retail IFRS Loss Ratio:** ~68% (vs. 66% prior year) * **Group IFRS Loss Ratio:** ~61% (vs. 58% prior year) * **NPS Score:** 57 overall · High 60s for cashless discharge * **Claim Rejection Rate:** ~7% FY25 ## B. Loss Ratio Drivers * **Significant Underwriting Improvement:** Combined ratio sharply improved to 2% on IFRS, reflecting stronger underwriting discipline and operational normalization post-service suspension. * **Loss Ratio Inflation Explained:** Reported deterioration in loss ratios driven by **accounting changes** (1/n and UPR 50% methods) and **timing mismatches** on large corporate policies, not underlying claims volatility. * **Claims Trend Stability:** No unusual patterns in ACS or incidence rates; performance remains range-bound despite short-term reserve pressures. * **Mix and Reserving Impact:** Retail and group loss ratios rose ~2% and ~3% respectively, primarily due to **reserve strengthening** and **shift toward large corporate clients**, not adverse claims experience. ## C. IBNR & Reserves * **Prudent Reserve Build-Up:** Incremental IBNR and outstanding claims increased due to temporary **suspension of auto-adjudication**, with reserves maintained conservatively without offsetting, supporting future ratio relief. * **Reserves Unaffected by 1/n Accounting:** IBNR and provisions remain sound, with elevated ratios stemming from a **smaller NEP base**, not reserve inadequacy. * **Forward-Looking Relief:** Q1 reserve strengthening expected to contribute to **lower loss ratios in coming quarters**, pending performance monitoring. ## D. Claim Settlement Trends * **Stable Settlement Discipline:** Rejection rate held at ~7%, with **retail settlement ratios in the 92–94% range**, while corporate policies show higher settlement rates. * **Customer Experience Gains:** PPN network now spans **43 cities**, processing **17% of claims** in those areas, enhancing access and experience. * **Operational Normalization:** Auto-adjudication fully resumed in Q2 (July) with **no abnormal trends** in claims volume or size, confirming system integrity. --- # 4. Distribution & Channels ## A. Key Figures * **Banca Channel Growth:** **>20%** YoY ## B. Channel Mix Stability * **SME-Centric Strategy:** Corporate focus remains on SMEs via agents, banks, digital partners, brokers, and own teams, with selective engagement in large corporate deals where integrated care value and pricing align. * **Pricing Advantage:** SME segment exhibits lower price sensitivity due to distribution through large SME-lending banks and proprietary agents, reinforcing margin resilience. ## C. Sales Headcount Expansion * **Distribution Investment:** Despite stable channel mix this quarter, company is actively expanding sales headcount through Q3 to strengthen reach and capacity. --- # 5. Pricing & Product Strategy ## A. Key Figures * **Price Increase:** **7%** flagship product (Q1 FY26) · **0%** same product (FY25) * **Health App Metrics:** **12.3 Mn** downloads · **5.7 Lakh** monthly active users * **Monthly Engagements:** **>50,000** health checkups · **>6,000** doctor consultations ## B. Price Hike Implementation * **Inflation-Driven Pricing:** High-single-digit price revisions enacted on mature products, primarily to offset **medical cost inflation**, with flagship product seeing first hike in over a year. * **Competitive Pressure:** Pricing discipline challenged by **aggressive competition in group/employer segment**, though recent wins validate adequate pricing power. ## C. LTV vs Zonal Pricing * **Pricing Model Evolution:** Core LTV-based framework remains, but **zonal pricing is being expanded** to improve risk-based differentiation, with potential for more zones in select products. * **Regional Risk Refinement:** Current use of **3–4 zones** allows for targeted premium adjustments, supporting better underwriting outcomes. ## D. Product Innovation * **Ecosystem-Led Differentiation:** Strategic shift toward being a **comprehensive health partner**, leveraging app engagement to drive retention and preventive care. * **Chronic Care Program Launch:** New Q1 initiative targeting diabetes, CVD, and metabolic conditions aims to **reduce long-term claims via early intervention and lifestyle management**. * **Commercial Validation:** Recent wins with **two large multinationals** underscore strength of integrated offering and pricing resilience. --- # 6. Technology & Operations ## A. Key Figures * **Cashless Approval Speed:** **76%** within 30 minutes (down from 90%) ## B. Core System Upgrade * **Major System Transition:** Migration to the **Oracle Health stack** set for Q2 go-live, representing a foundational upgrade to core IT infrastructure. ## C. AI & Analytics Tools * **AI-Driven CX Enhancement:** Full-scale rollout of **Sprinklr** platform underway to strengthen customer experience management. * **Call Quality Monitoring:** **Convin**, an AI-powered call analytics tool, now live across customer and telesales interactions to ensure service consistency. ## D. Auto-Adjudication Status * **Claims Processing Disruption:** Auto-adjudication paused in Q1 due to third-party security reviews, leading to **slower cashless approvals** and SLA pressures. --- # 7. Risks & Regulatory Factors ## A. Key Figures * **Healthcare Providers in Empanelment Pipeline:** **~1,500** providers at various application stages ## B. Claims Processing Risk * **Claims Monitoring Underway:** Company to assess claims pattern shifts over next two quarters to determine if changes are structural or temporary. ## C. Medical Inflation Pressure * **Industry-Led Cost Containment:** General Insurance Council推动 evidence-based medical protocols to curb unnecessary care, particularly during post-monsoon infection spikes. ## D. Regulatory Compliance * **Standardization Drive Accelerating:** Common empanelment initiative with **standardized tariffs** and agreements underway, aimed at enhancing affordability and sector coordination. --- # 8. Guidance & Outlook ## A. Key Figures * EOM Ratio: 35.9% in Q1 FY26 (-4.8% YoY) · 40.7% in Q1 FY25 * **GWP Growth:** **28%** YoY in Q1 FY26 * **Retail Market Share:** **10%** (up from 9% YoY) ## B. Full-Year EOM Target * **Efficiency Gains Continue:** EOM ratio improved YoY on the back of operating leverage, lower commission intensity, and disciplined cost control. * **Regulatory Compliance in Sight:** On track to meet IRDA’s EOM glide path, with only **10 bps gap remaining** to full compliance. ## C. Loss Ratio Trajectory * **Claims Stabilization Expected:** Management anticipates loss ratio stabilization by year-end, supported by lower claim incurrence trends. ## D. Market Share Projection * **Market Share Resilience:** Retail market share held at **10%** despite aggressive peer pricing on long-term policies, underscoring pricing discipline. * **Industry Tailwinds:** Positioned to benefit from rising health insurance awareness, driving structural volume growth.